Nanobiotix Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-23.96	-68.13	-39.7	-57.04	-47
Depreciation & Amortization	1.5	1.62	1.51	1.5	1.56
Stock-Based Compensation	3.54	4.3	3.22	3.17	3.2
Other Adjustments	-10.9	28.44	12.58	12.96	0.83
Change in Receivables	0.84	-2.07	-0.81	-0.1	0.06
Changes in Accounts Payable	-5.41	1.96	8.68	2.91	-0.28
Changes in Accrued Expenses	0.18	-0.22	0.72	1.22	-1.65
Changes in Income Taxes Payable	-0.2	-0.06	-0.01	-	-
Changes in Unearned Revenue	-0.02	12.19	1.61	-	16.52
Changes in Other Operating Activities	1.01	2.43	-0.28	-1.73	-3.11
Operating Cash Flow	-33.42	-19.55	-12.48	-37.1	-29.87
Capital Expenditures	-0.54	-0.85	-0.33	-0.09	-0.23
Purchases of Intangible Assets	-0.01	-0	-0.01	-0	-0.01
Other Investing Activities	-0.03	-0.11	-0.01	0.23	-0.01
Investing Cash Flow	-0.58	-0.96	-0.35	0.14	-0.24
Long-Term Debt Issued	42.93	-	0.15	-	-
Long-Term Debt Repaid	-3.55	-3.08	-2.97	-3.64	-2.83
Net Long-Term Debt Issued (Repaid)	39.38	-3.08	-2.82	-3.64	-2.83
Issuance of Common Stock	1.54	-	60.15	-	0.04
Net Common Stock Issued (Repurchased)	1.54	-	60.15	-	0.04
Other Financing Activities	-3.5	-2.06	-10.56	-2.01	-2.39
Financing Cash Flow	37.42	-5.14	46.77	-5.65	-5.18
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.4	0.09	-0.05	0.08	0.06
Net Cash Flow	3.01	-25.55	33.9	-42.53	-35.23
Free Cash Flow	-33.96	-20.4	-12.8	-37.2	-30.1
FCF Margin	-104.19%	283.69%	-35.36%	-778.79%	-1137.14%
Free Cash Flow Per Share	-0.71	-0.43	-0.35	-1.07	-0.87
Levered Free Cash Flow	11.94	-54.14	-30.62	-56.88	-37.03
Unlevered Free Cash Flow	-14.3	-51.43	-14.96	-42.9	-39.77

SEC Filings: 10-K · 10-Q